The Latest Urologic Oncology Journal Articles

Keep up to date with the latest in urologic oncology. Check out the latest diabetes articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily

• Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration.20th September 2020
  Despite being the most frequent renal fusion anomaly, tumors arising from horseshoe kidneys (HSKs) are extremely rare and management guidance is lacking.To evaluate the perioperative, oncological, and functional outcomes of surgically treated HSK tumors.A retrospective, multicenter cohort study of 43 HSK tumors in 40 patients was conducted, and technical description of the surgical approach has […]
• Hybrid Indocyanine Green-99mTc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution.20th September 2020
  Sentinel node (SN) biopsy in penile cancer (PeCa) is typically performed using 99mTc-nanocolloid and blue dye. Recent reports suggested that the hybrid (radioactive and fluorescent) tracer indocyanine green (ICG)-99mTc-nanocolloid may improve intraoperative optical SN identification.The current study aimed to confirm the reliability of ICG-99mTc-nanocolloid and to assess whether blue dye is still of added value.A […]
• A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy.18th September 2020
  Prostate cancer is predominantly indolent at diagnosis with a small fraction (15-25%) representing aggressive subtype [Gleason score (GS) 7-10], which is prone to metastatic progression. It is critical to explore non-invasive assays for the early detection of this aggressive subtype, when it still can be treated effectively. Additionally, there is an emerging need to develop […]
• Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging.18th September 2020
  The feasibility and efficacy of robot-assisted radical prostatectomy (RARP) in locally advanced prostate cancer (PCa) patients with iT3 lesion at magnetic resonance imaging (MRI) are currently not explored.To describe our revised RARP technique (ie, superextended RARP [SE-RARP]) for PCa patients with posterior iT3a or iT3b at MRI.Data from 89 patients with posterior iT3a or T3b […]
• A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes.18th September 2020
  Obesity is a well-known risk factor for kidney cancer incidence. However, a number of studies have demonstrated more favorable kidney cancer prognosis in patients with elevated body mass index (BMI) conferring a survival advantage, termed ‘the obesity paradox’. We aimed to evaluate the association between BMI and kidney cancer outcomes (progression-free survival (PFS), cancer specific […]
• Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.17th September 2020
  Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free […]
• Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.16th September 2020
  Restaging of prostate cancer in patients with biochemical recurrence (BCR) after radical treatment remains a challenging clinical scenario as current imaging modalities are suboptimal. To date, PSMA PET/CT seems to represent a very promising diagnostic tool in this setting. Therefore, we evaluated the detection rate (DR) of several PET/CT PSMA-based tracers in the restaging of […]
• Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy, and Retroperitoneal Lymph Node Dissection for the Management of Early-Stage Testicular Germ Cell Tumors: A Systematic Review.11th September 2020
  Cancer-specific survival for men with early-stage (Stage I-IIB) testicular germ cell tumors (TGCT) is greater than 90% with any management strategy. The data regarding the comparative effectiveness of surveillance, primary chemotherapy, radiotherapy, and retroperitoneal lymph node dissection (RPLND) was synthesized with a focus on oncologic outcomes, patient-reported outcomes, and short- and long-term toxicities.PubMed, Embase® and […]
• Apalutamide and Overall Survival in Prostate Cancer.10th September 2020
  The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.We report the prespecified event-driven final analysis for OS.A total of 1207 […]
• Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.10th September 2020
  Life expectancy has become a core consideration in prostate cancer care. While multiple prediction tools exist to support decision-making, their discriminative ability remains modest, which hamper usage and utility. We examined whether combining patient-reported and claims-based health measures into prediction models improves performance.Using SEER-CAHPS, we identified men ≥65 years old diagnosed with prostate cancer from […]
• Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.9th September 2020
  Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at […]
• High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.9th September 2020
  We report outcomes of hemigland high intensity focused ultrasound ablation as primary treatment for localized prostate cancer in the United States.A total of 100 consecutive men underwent hemigland high intensity focused ultrasound (December 2015 to December 2019). Primary end point was treatment failure, defined as Grade Group 2 or greater on followup prostate biopsy, radical […]
• Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case-Controlled Study.9th September 2020
  Radical nephrectomy with tumor thrombectomy is considered standard of care in patients with renal cell carcinoma (RCC). Surgical ligation and interruption of the inferior vena cava (IVC), however, is sometimes necessary when the tumor thrombus invades the IVC wall. This study assesses the outcomes in patients with RCC undergoing IVC ligation compared to IVC thrombectomy.We […]
• Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2.8th September 2020
  TMPRSS2 is a host co-receptor for cell entry of SARS-CoV-2. One prior report suggested that use of androgen deprivation therapy (ADT), which downregulates TMPRSS2, may protect men with prostate cancer from infection.Cohort study of a prospective registry of all patients tested for SARS-CoV-2 between March 12 and June 10, 2020, with complete follow-up until disease […]
• Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes Following Radical Cystectomy.8th September 2020
  Frailty is associated with adverse outcomes following radical cystectomy. Prospective tools to identify factors affecting outcomes are needed. We describe a novel electronic rapid fitness assessment to evaluate geriatric patients undergoing radical cystectomy.Prior to undergoing radical cystectomy between February 2015 and February 2018, 80 patients over the age of 75 completed the electronic rapid fitness […]
• Clinical Utility of 4Kscore, ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High-Grade Prostate Cancer.8th September 2020
  We aimed to evaluate 4Kscore and ExosomeDx with multiparametric magnetic resonance imaging (mpMRI) in the detection of high-grade prostate cancer (PCa) and number of biopsies avoided.Patients had one liquid biomarker test with or without mpMRI. High-grade PCa was defined as Gleason grade group (GG) ≥2. The overall number of avoided biopsies (with GG≤1), and number […]
• Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing.8th September 2020
  BackgroundTo explore the genomic profiles of Chinese patients with castration-sensitive prostate cancer(CSPC) and those with metastatic castration-resistant prostate cancer(mCRPC) via germline and circulating tumor DNA(ctDNA) sequencing.MethodsA hybridization capture-based next-generation sequencing assay was used to identify germline and somatic alterations in 50 genes, including androgen receptor(AR) pathway genes, DNA damage repair(DDR) pathway genes, TP53, and RB1.ResultsWe […]
• Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.2nd September 2020
  Perioperative chemotherapy (neoadjuvant or adjuvant) has been developed to increase overall survival for nonmetastatic muscle-invasive bladder cancer (MIBC). Retrospective studies or prospective phase II trials have been reported to use dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC). As dd-MVAC has shown higher response rates in metastatic disease, better efficacy is […]
• The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.29th August 2020
  The dogma that urine is sterile has been overturned and dysbiosis of the urinary microbiome has been linked to many urological disorders. We tested the hypothesis that the urinary microbial composition may be different between men with or without bladder cancer in catheter-collected urines, bladder washouts and midstream voided urines, and may be dependent on […]
• The Risk of New Onset Dementia And/Or Alzheimer’s Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.29th August 2020
  Androgen deprivation therapy (ADT) is a standard therapy for some localized and almost all metastatic prostate cancer (PCa) patients. Although several clinical cohort studies have identified an impact of ADT on the cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer’s […]
• The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.29th August 2020
  The dogma that urine is sterile has been overturned and dysbiosis of the urinary microbiome has been linked to many urological disorders. We tested the hypothesis that the urinary microbial composition may be different between men with or without bladder cancer in catheter-collected urines, bladder washouts and midstream voided urines, and may be dependent on […]
• The Risk of New Onset Dementia And/Or Alzheimer’s Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.29th August 2020
  Androgen deprivation therapy (ADT) is a standard therapy for some localized and almost all metastatic prostate cancer (PCa) patients. Although several clinical cohort studies have identified an impact of ADT on the cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer’s […]
• Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.28th August 2020
  Infigratinib (BGJ398) is a potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor with significant activity in metastatic urothelial carcinoma (mUC) bearing FGFR3 alterations. It can cause hyperphosphatemia due to the “on-target” class effect of FGFR1 inhibition.To investigate the relationship between hyperphosphatemia and treatment response in patients with mUC.Oral infigratinib 125 mg/d for 21 d every […]
• Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.21st August 2020
  Standard of care for patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by consolidative therapy with either chemoradiation or radical cystectomy (RC). Some patients experience robust pathologic responses to NAC, and these have been reported to associate with somatic mutations in specific gene pathways including DNA damage response genes.To evaluate the […]
• Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.20th August 2020
  The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel previously. In a prior analysis, the trial’s primary endpoint (overall survival [OS]) was not improved significantly.To report the final analysis of OS.A total of 799 patients were randomized […]
• Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.18th August 2020
  Family history of prostate cancer (PCa) is a well-known risk factor, and both common and rare genetic variants are associated with the disease.To detect new genetic variants associated with PCa, capitalizing on the role of family history and more aggressive PCa.A two-stage design was used. In stage one, whole-exome sequencing was used to identify potential […]
• Pathologic and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed with Cystectomy with or Without Neoadjuvant Chemotherapy.12th August 2020
  Although neoadjuvant chemotherapy (NAC) is associated with a survival advantage in pure urothelial (PUC) muscle-invasive bladder cancer (MIBC), the role of NAC is less clear in variant histology (VH) or urothelial carcinoma with divergent differentiation (UDD). We compared chemotherapy response and survival outcomes of patients with non-PUC histology who were managed with NAC followed by […]
• Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.6th August 2020
  Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs).To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.The authors conducted a retrospective review and comparison of patients having (1) MIBC treated with neoadjuvant chemotherapy (NAC), […]
• Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy.5th August 2020
  Over the years, several techniques for performing robot-assisted prostatectomy have been implemented in an effort to achieve optimal oncological and functional outcomes.To provide an evidence-based description and video-based illustration of currently available dissection techniques for robotic prostatectomy.A literature search was performed to retrieve articles describing different surgical approaches and techniques for robot-assisted radical prostatectomy (RARP) […]
• Lymph Node Mapping in Penile Cancer Patients Undergoing Pelvic Lymph Node Dissection.5th August 2020
  A map of pelvic lymph node metastasis (LNM) in penile cancer patients helps to clarify the pattern of pelvic spread and define the reasonable limits of dissection. It hasn’t been established. We aim to provide an accurate map of LNM in penile cancer patients and determine the reasonable extent of pelvic lymph node dissection (PLND).We […]
• The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.2nd August 2020
  Instillation therapy for non-muscle-invasive bladder cancer (NMIBC) reduces recurrences but is associated with side effects. Preoperative instillation of chemotherapy could potentially be associated with fewer side effects compared with adjuvant instillations and in some patients make tumour resection (transurethral resection of the bladder tumour [TURBT]) superfluous.To investigate tumour response and adverse events related to short-term, […]
• The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance.29th July 2020
  Evidence suggests that visceral fat quantity may be associated with post-prostatectomy outcomes and risk of prostate cancer-related death. We aimed to evaluate if increased fat volume, normalized to prostate size, is associated with decreased risk of disease progression.Patients enrolled on a prospective active surveillance trial for at least 6 months who had an MRI within […]
• How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?28th July 2020
  To uncover the optimal number of transperineal magnetic resonance imaging ultrasound (MRI/US) fusion targeted biopsy (TB) cores per lesion needed for detection of clinically significant prostate cancer (csPCa).A total of 101 patients with at least 1 lesion with a PI-RADS (Prostate Imaging Reporting and Data System) score of 3 or greater were recruited prospectively. At […]
• Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer.28th July 2020
  Treatment for muscle-invasive bladder cancer (MIBC) includes radical cystectomy (RC), a major surgery that can be associated with significant toxicity. Limited data exist related to changes in patients’ global health status and recovery following RC. We sought to use geriatric assessment (GA) to longitudinally compare health-related impairments in older and younger patients with MIBC who […]
• Robotic-Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer.28th July 2020
  Robotic-assisted retroperitoneal lymph node dissection (R-RPLND) in patients with testicular cancer (TC) is controversially discussed. Lately, unusual recurrence patterns with adverse outcome have been published after R-RPLND. Aim of this report is to determine the feasibility, safety and early oncological outcome of R-RPLND in patients with small volume metastatic TC.We retrospectively evaluated 27 consecutive patients […]
• A Systematic Review and Meta-analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.28th July 2020
  The currently available evidence regarding the prognostic and clinical significance of each Variant histology (VH) subtype remains scarce. Therefore, we aimed to assess the prognostic value of VH in patients with Urothelial carcinoma of the bladder (UCB) treated with radical cystectomy.The PubMed, Web of Science, Cochrane Library, and Scopus databases were searched for articles published […]
• Risk Stratification of Prostate Cancer According to PI-RADS Version 2 Categories: Meta-Analysis for Prospective Studies.28th July 2020
  The Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) categorizes the likelihood of clinically significant prostate cancer (csPCa) on magnetic resonance imaging (MRI) and determines the diagnostic pathway. We aimed to determine csPCa and all PCa detection rates in each PI-RADSv2 category.MEDLINE, EMBASE, and Cochrane databases were searched for prospective studies reporting the […]
• PIRADS Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.28th July 2020
  To identify baseline imaging and clinical characteristics of patients that may improve risk stratification among patients being evaluated for active surveillance (AS).From July 2007 to January 2020, patients referred to our institution for prostate cancer were evaluated and those that remained on AS were identified. Men underwent multiparametric MRI (mpMRI) upon entry into our AS […]
• Microhematuria: AUA/SUFU Guideline.24th July 2020
  Patients presenting with microhematuria represent a heterogeneous population with a broad spectrum of risk for genitourinary malignancy. Recognizing that patient-specific characteristics modify the risk of underlying malignant etiologies, this guideline sought to provide a personalized diagnostic testing strategy.The systematic review incorporated evidence published from January 2010 through February 2019, with an updated literature search to […]
• The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.24th July 2020
  This systematic review and meta-analysis aimed to assess the prognostic impact of intraductal carcinoma of the prostate (IDC-P) in patients with prostate cancer (PCa).A systematic search was performed according to the Preferred Reporting Items for Systemic Review and Meta-analysis statement. We searched PubMed, Web of Science, Cochrane Library, and Scopus databases up to October 2019. […]
• Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland’s Quality Performance Indicators Programme.22nd July 2020
  Clinical outcomes from non-muscle-invasive bladder cancer (NMIBC) are partly determined by the quality of initial interventions. To improve and standardise treatment for cancer, Scotland implemented a national Quality Performance Indicator (QPI) programme for bladder cancer (BC).To evaluate compliance with specific quality indicators (QIs) related to transurethral resection of bladder tumour (TURBT) and to understand clinical […]
• Delaying Cancer Cases in Urology during COVID-19: Review of the Literature.22nd July 2020
  Coronavirus Disease 2019 (COVID-19) is a global pandemic affecting hospital systems and the availability of resources for surgical procedures. Our aim is to provide guidance for urologists to help prioritize urologic cancer surgeries.We reviewed published literature on bladder cancer, upper tract urothelial carcinoma (UTUC), penile cancer, testis cancer, prostate cancer, renal cancer, and adrenal cancer.For […]
• Identification of Differential Tumor Subtypes of T1 Bladder Cancer.21st July 2020
  Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle-invasive bladder cancers (NMIBCs). Most T1 cancers are treated with bacillus Calmette-Guérin (BCG), but many will progress or recur, and some T1 patients will die from bladder cancer. Particularly aggressive tumors could be treated with early cystectomy. To better understand the molecular […]
• FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.20th July 2020
  Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-invasive BC. We analyzed FGFR3 mutations, FGFR3, and p53 protein expression and assessed their prognostic value in a […]
• Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort.19th July 2020
  Most reports of active surveillance (AS) of small renal masses (SRMs) lack biopsy confirmation, and therefore include benign tumors and different subtypes of renal cell carcinoma (RCC).We compared the growth rates and progression of different histologic subtypes of RCC SRMs (SRMRCC) in the largest cohort of patients with biopsy-characterized SRMs on AS.Data from patients in […]
• Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.15th July 2020
  Antibiotic effects on the gut microbiota may negatively impact survival with immune checkpoint inhibitors (ICIs). However, there is minimal evidence regarding whether antibiotic impacts are specific to ICIs or impacts in urothelial carcinoma (UC). In a post hoc analysis of IMvigor210 (single-arm atezolizumab) and IMvigor211 (phase III randomised trial of atezolizumab vs chemotherapy), the association […]
• Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.14th July 2020
  Patients with metastatic renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and have shown limited responsiveness to inhibition of the VEGF pathway. We conducted a prespecified analysis of the randomised, phase 3 IMmotion151 trial in previously untreated patients with advanced or metastatic RCC to assess the effectiveness of atezolizumab + bevacizumab versus sunitinib in […]
• Active Surveillance for Men with Intermediate Risk Prostate Cancer.13th July 2020
  Optimal treatment of intermediate risk prostate cancer remains unclear. National Comprehensive Cancer Network guidelines recommend active surveillance, prostatectomy or radiotherapy. Recent trials demonstrated no difference in prostate cancer specific mortality for men undergoing active surveillance for low risk prostate cancer compared to prostatectomy or radiotherapy. The use of active surveillance for intermediate risk prostate cancer […]
• Mutiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.8th July 2020
  Multiparametric magnetic resonance imaging (mpMRI) has improved the detection of clinically significant prostate cancer. It remains unclear, however, whether mpMRI can safely replace confirmatory or surveillance biopsies in men with low-risk disease managed with active surveillance (AS). Overall, 166 men were upgraded at a median of 29 mo (interquartile range 13-54). The overall negative predictive […]
• ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer.8th July 2020
  Prostate cancer (PCa) is the most prevalent solid cancer among men in Western Countries. The clinical behavior of localized PCa is highly variable. Some cancers are aggressive leading to death, while others can even be monitored safely. Hence, there is a high clinical need for precise biomarkers for identification of aggressive disease in addition to […]
• Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.8th July 2020
  The potential for low-grade (grade group 1 [GG1]) prostate cancer (PCa) to progress to high-grade disease remains unclear.To interrogate the molecular and biological features of low-grade PCa serially over time.Nested longitudinal cohort study in an academic active surveillance (AS) program. Men were on AS for GG1 PCa from 2012 to 2017.Electronic tracking and resampling of […]
• A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.7th July 2020
  Cyclic high-dose testosterone injections, also known as bipolar androgen therapy (BAT), is a novel treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). BAT has shown clinical activity in prior studies enrolling men with mCRPC and may potentially restore sensitivity to prior androgen receptor (AR)-targeted agents.To evaluate the clinical activity of BAT in patients […]
• Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.7th July 2020
  Long-term outcomes of patients treated with salvage lymph node dissection (sLND) for nodal recurrence of prostate cancer (PCa) remain unknown.To investigate long-term oncological outcomes after sLND in a large multi-institutional series.The study included 189 patients who experienced prostate-specific antigen (PSA) rise and nodal-only recurrence after radical prostatectomy (RP) and underwent sLND at 11 tertiary referral […]
• Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.7th July 2020
  Recently, mutations in speckle-type pox virus and zinc finger protein (SPOP) gene (mutant SPOP [mtSPOP]) have been associated with improved outcomes to abiraterone in the castration-resistant setting. We hypothesized that mtSPOP would be associated with improved outcomes to systemic therapy in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC). Retrospective data of newly diagnosed […]
• Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.7th July 2020
  The best surgical template for salvage pelvic lymph node dissection (sLND) in patients with nodal recurrence from prostate cancer (PCa) after radical prostatectomy (RP) is currently unknown. We analyzed data of 189 patients with a unilateral positive positron emission tomography (PET) scan of the pelvic lymph node areas, who were treated with bilateral pelvic sLND […]
• Risk of Prostate Cancer after a Negative MRI-Guided Biopsy.3rd July 2020
  An MRI-guided biopsy (MRGB), which reveals no cancer, may impart reassurance beyond that offered by ultrasound-guided biopsy. However, follow-up of men after a negative MRGB has been mostly by PSA testing; reports of follow-up tissue confirmation are few. We investigated incidence of clinically significant prostate cancer (csPCa) in such men who, because of persistent cancer […]
• Impact of Time-To-Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma.3rd July 2020
  The time between radiographic identification of a renal tumor and surgery can be concerning for patients and clinicians due to fears of tumor progression while awaiting treatment. This study aimed to evaluate the association between surgical wait time and oncologic outcomes for patients with renal cell carcinoma (RCC).The Canadian Kidney Cancer information system (CKCis) is […]
• Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.2nd July 2020
  Androgen deprivation therapy is the mainstay treatment of metastatic prostate cancer, achieved mainly by gonadotropin-releasing hormone (GnRH) agonists or antagonists.To investigate the differential impact of GnRH agonists and antagonists on clinical safety and oncologic outcomes.This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A literature search using […]
• Intra-prostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.1st July 2020
  Men who fail external beam radiotherapy (EBRT) are usually placed on delayed hormone therapy. Some of these men have localised recurrence that might be suitable for further local therapy. We aimed to describe patterns of recurrence, and suitability for focal ablative therapy, in those undergoing transperineal template prostate-mapping (TTPM) biopsies.145 consecutive patients (December 2007-May 2014) […]
• European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.29th June 2020
  The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice.To provide an overview of the EAU guidelines on UTUC as an aid to clinicians.The recommendations provided in the current […]